Video Experimental Relacionado

Updated: Jul 16, 2026

Quantifying Single Microvessel Permeability in Isolated Blood-perfused Rat Lung Preparation
07:22

Quantifying Single Microvessel Permeability in Isolated Blood-perfused Rat Lung Preparation

Published on: June 30, 2014

Biodisponibilidad de la heparina de bajo peso molecular subcutánea para pacientes con vasopresores

Janine Dörffler-Melly, Evert de Jonge, Anne-Corneliede Pont

    Lancet (London, England)
    |March 19, 2002
    PubMed
    Resumen

    Los pacientes en unidades de cuidados intensivos (UCI) que reciben vasopresores muestran una eficacia reducida de la heparina de bajo peso molecular (LMWH) para prevenir la tromboembolía venosa. Esto sugiere la necesidad de ajustar la dosificación o administración de LMWH en estos pacientes críticos.

    Más Videos Relacionados

    Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay08:43

    Evaluating Vascular Hyperpermeability-inducing Agents in the Skin with the Miles Assay

    Published on: June 19, 2018

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

    Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

    Published on: June 18, 2020

    Videos de Conceptos Relacionados

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...